title: CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
authors: Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan.
authors: Ayako
authors: A
authors: Ito
authors: Kazunari
authors: K
authors: Sugita
authors: Koji
authors: K
authors: Adachi
authors: Yuzuru
authors: Y
authors: Hosoda
authors: Toru
authors: T
authors: Motokura
authors: Osamu
authors: O
authors: Yamamoto
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D011237:Predictive Value of Tests; D011239:Prednisolone / Q000627:therapeutic use; D054398:Receptors, CCR4 / Q000032:analysis*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C515354:CCR4 protein, human; D005938:Glucocorticoids; D054398:Receptors, CCR4; D011239:Prednisolone; C549035:mogamulizumab